Navigation Links
Analyzing The Side Effects Of Sirolimus Stents

Based on findings of a recent study researchers from Sweden say they have found that implantation //of a sirolimus-eluting stent is associated with coronary vasoconstriction in areas adjacent to the treated vessel that is not seen with bare metal stents.

Sirolimus-eluting stents are widely used for percutaneous coronary interventions because of their excellent long-term clinical and angiographic outcome, however, recent concerns have been raised that the stents could lead to increased rates of stent thrombosis due to delayed or absent endothelialization.

Researchers compared endothelial function and coronary vasomotor response to exercise in 14 patients fitted with sirolimus-eluting stents and 11 control patients receiving bare metal stents. It was observed that after 6 months, the reference vessel showed an increase in exercise-induced vasodilation in both groups, with a mean increase in diameter of 13%, and no vasomotion in the stented vessel segments. In adjacent segments that were proximal and distal to the bare metal stent there were also increases in exercise-induced vasodilation of 15% and 17%, respectively. In contrast, exercise-induced vasoconstriction - indicating endothelial dysfunction - occurred with the sirolimus-eluting stent at these locations, with decreases in vessel diameter of 12% and 15%, respectively (p<0.001 vs controls). Vasodilatory capacity was preserved, with sublingual nitroglycerin associated with maximal vasodilation of these vessel segments in both groups.

Researchers are of the opinion that Paradoxic vasoconstriction in a vessel segment not subjected to percutaneous transluminal coronary angioplasty barotrauma may be due to diffusion of the antiproliferative drug from the stent to the peri-stent region, inducing endothelial dysfunction. However some are of the opinion that inadequate endothelial coverage could lead to insufficient nitric oxide to promote normal vasodilation with exercise. In concl usion researchers say that they will not be able to come to any positive finding, until further studies are done in this field.

For more information read:


Related medicine news :

1. Analyzing The Side Effects Of Some Common Medications
2. Analyzing The Risk Factors For Diabetic Neuropathy
3. Analyzing Client-Centered Therapy.
4. Acupuncture May Help Chemotherapy Side Effects
5. Chemotherapy Pill Has Fewer Side Effects Than IV
6. Therapy Boosts Chemotherapy Effects
7. Smoking and its Effects
8. Reducing The After Effects of Tonsillectomy
9. The Side Effects Of Estrogen Therapy
10. The Harmful Effects Of Cigarette Smoke
11. Lung Therapy Found To Have Long-Term Side Effects
Post Your Comments:

(Date:11/27/2015)... Raleigh, NC (PRWEB) , ... November 27, 2015 , ... ... most effective ways to treat it. Surviving Mesothelioma has just posted the findings ... Researchers at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, ... The digital component is distributed nationally, through a vast social media strategy and ...
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
(Date:11/27/2015)... ... , ... CBD College is proud to announce that on November ... to its Diagnostic Medical Sonography program. CBD College is honored to join this very ... and universities in the state of California make the cut. CBD College is officially ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)... 25, 2015 AAIPharma Services Corp./Cambridge Major ... at least $15.8  Million to expand its laboratories ... . The expansion will provide additional office ... growing demands of the pharmaceutical and biotechnology markets. ... will provide up to 40,000 square feet of ...
Breaking Medicine Technology: